Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide

mAbs

Volumn 6, Issue 4, 2014, Pages 871-878

  Walter, Sarah ^a   Alibhoy, Abbas ^a   Escandon, Rafael ^a   Bigal, Marcelo E ^a  

^a TEVA PHARMACEUTICALS   (Israel)

Author keywords

Antibody; Cardiovascular; CGRP; Hemodynamic; Migraine; Safety

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; LBR 101; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; EXPERIMENTAL MONKEY; FEMALE; HEART RATE; HEMODYNAMIC PARAMETERS; HEMODYNAMICS; LONG TERM CARE; MACACA FASCICULARIS; MALE; MULTIPLE DRUG DOSE; NONHUMAN; QT INTERVAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TELEMETRY; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; IMMUNOLOGY; MIGRAINE DISORDERS; PATHOPHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; CALCITONIN GENE-RELATED PEPTIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; HEMODYNAMICS; HUMANS; MACACA FASCICULARIS; MALE; MIGRAINE DISORDERS;

EID: 84903783970     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.29242     Document Type: Article

References (37)

1. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33:48-56; PMID:8388188; http://dx.doi.org/10.1002/ ana.410330109
2. Edvinsson L, Goadsby PJ. Extracerebral manifestations in migraine. A peptidergic involvement? J Intern Med 1990; 228:299-304; PMID:2266336; http://dx.doi.org/10.1111/j.1365-2796.1990.tb00236.x
3. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28:183-7; PMID:1699472; http://dx.doi.org/10.1002/ana.410280213
4. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22:54-61; PMID:11993614; http://dx.doi.org/10.1046/j.1468-2982.2002.00310.x
5. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin generelated peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372:2115-23; PMID:19036425; http://dx.doi.org/10.1016/S0140-6736(08)61626-8
6. Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011; 31:712-22; PMID:21383045; http://dx.doi.org/10.1177/ 0333102411398399
7. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM; BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350:1104-10; PMID:15014183; http://dx.doi.org/10. 1056/NEJMoa030505
8. Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther 2013; 93:78-85; PMID:23212108; http://dx.doi.org/10.1038/clpt.2012.198
9. Hoffmann J, Goadsby PJ. New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors. Curr Treat Options Neurol 2012; 14:50-9; PMID:22090312; http://dx.doi.org/10.1007/s11940-011-0155-4
10. Wu H, Dall'Acqua WF. Humanized antibodies and their applications. Methods 2005; 36:1-2; PMID:15848069; http://dx.doi.org/10.1016/j.ymeth.2005.02.001
11. Allen DM, Chen LE, Seaber AV, Urbaniak JR. Calcitonin gene-related peptide and reperfusion injury. J Orthop Res 1997; 15:243-8; PMID:9167627; http://dx.doi.org/10.1002/jor.1100150213
12. Källner G, Gonon A, Franco-Cereceda A. Calcitonin gene-related peptide in myocardial ischaemia and reperfusion in the pig. Cardiovasc Res 1998; 38:493-9; PMID:9709411; http://dx.doi.org/10.1016/ S0008-6363(98)00016-9
13. Lynch JJ Jr., Detwiler TJ, Kane SA, Regan CP. Effect of calcitonin gene-related peptide receptor antagonism on the systemic blood pressure responses to mechanistically diverse vasomodulators in conscious rats. J Cardiovasc Pharmacol 2010; 56:518-25; PMID:20729756; http://dx.doi.org/10.1097/ FJC.0b013e3181f5d414
14. Supowit SC, Ethridge RT, Zhao H, Katki KA, Dipette DJ. Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats. Am J Physiol Heart Circ Physiol 2005; 289:H1169-75; PMID:15879482; http://dx.doi.org/10.1152/ajpheart.00973.2004
15. Chan KY, Edvinsson L, Eftekhari S, Kimblad PO, Kane SA, Lynch J, Hargreaves RJ, de Vries R, Garrelds IM, van den Bogaerdt AJ, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther 2010; 334:746-52; PMID:20573757; http://dx.doi.org/10.1124/jpet.110.165993
16. Lynch JJ, Shen YT, Pittman TJ, Anderson KD, Koblan KS, Gould RJ, Regan CP, Kane SA. Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs. Eur J Pharmacol 2009; 623:96-102; PMID:19766109; http://dx.doi.org/10.1016/j.ejphar. 2009.09.018
17. Van der Schueren BJ, Blanchard R, Murphy MG, Palcza J, De Lepeleire I, Van Hecken A, Depré M, de Hoon JN. The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol 2011; 71:708-17; PMID:21480950; http://dx.doi.org/10.1111/j.1365-2125.2010.03869.x
18. Chaitman BR, Ho AP, Behm MO, Rowe JF, Palcza JS, Laethem T, Heirman I, Panebianco DL, Kobalava Z, Martsevich SY, et al. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina. Clin Pharmacol Ther 2012; 91:459-66; PMID:22278333; http://dx.doi.org/10.1038/clpt.2011.246
19. Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 2013; 53:1230-44; PMID:23848260; http://dx.doi.org/10.1111/head.12179
20. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010; 6:573-82; PMID:20820195; http://dx.doi.org/10.1038/nrneurol.2010.127
21. Vollbracht S, Rapoport AM. The pipeline in headache therapy. CNS Drugs 2013; 27:717-29; PMID:23839594; http://dx.doi.org/10.1007/s40263-013-0090-x
22. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999; 29:2613-24; PMID:10458776; http://dx.doi.org/10.1002/(SICI) 1521-4141(199908)29: 08〈2613: :AIDIMMU2613〉3.0.CO;2-J
23. Zeller J, Poulsen KT, Sutton JE, Abdiche YN, Collier S, Chopra R, Garcia CA, Pons J, Rosenthal A, Shelton DL. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol 2008; 155:1093-103; PMID:18776916; http://dx.doi.org/10.1038/bjp.2008.334
24. Klingbeil C, Hsu DH. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicol Pathol 1999; 27:1-3; PMID:10367664; http://dx.doi.org/10.1177/019262339902700101
25. Rodriguez I, Erdman A, Padhi D, Garnett CE, Zhao H, Targum SL, Balakrishnan S, Strnadova C, Viner N, Geiger MJ, et al. Electrocardiographic assessment for therapeutic proteins - scientific discussion. Am Heart J 2010; 160:627-34; PMID:20934555; http://dx.doi.org/10.1016/j.ahj.2010.07.001
26. Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, Garzone P. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia 2013; 34:483-92; PMID:24366980; http://dx.doi.org/10.1177/ 0333102413517775
27. Lu JT, Son YJ, Lee J, Jetton TL, Shiota M, Moscoso L, Niswender KD, Loewy AD, Magnuson MA, Sanes JR, et al. Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol Cell Neurosci 1999; 14:99-120; PMID:10532808; http://dx.doi.org/10.1006/ mcne.1999.0767
28. Oh-hashi Y, Shindo T, Kurihara Y, Imai T, Wang Y, Morita H, Imai Y, Kayaba Y, Nishimatsu H, Suematsu Y, et al. Elevated sympathetic nervous activity in mice deficient in alphaCGRP. Circ Res 2001; 89:983-90; PMID:11717154; http://dx.doi.org/10.1161/hh2301.100812
29. Walker CS, Li X, Whiting L, Glyn-Jones S, Zhang S, Hickey AJ, Sewell MA, Ruggiero K, Phillips AR, Kraegen EW, et al. Mice lacking the neuropeptide alpha-calcitonin gene-related peptide are protected against diet-induced obesity. Endocrinology 2010; 151:4257-69; PMID:20610563; http://dx.doi.org/10. 1210/en.2010-0284
30. Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord 2010; 3:369-78; PMID:21179597; http://dx.doi.org/10.1177/1756285610388343
31. Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med 2011; 13:e36; PMID:22123247; http://dx.doi.org/10.1017/S1462399411002067
32. Fisher LA, Kikkawa DO, Rivier JE, Amara SG, Evans RM, Rosenfeld MG, Vale WW, Brown MR. Stimulation of noradrenergic sympathetic outflow by calcitonin gene-related peptide. Nature 1983; 305:534-6; PMID:6604878; http://dx.doi.org/ 10.1038/305534a0
33. Le Mével JC, Lancien F, Mimassi N, Kermorgant M, Conlon JM. Central ventilatory and cardiovascular actions of calcitonin gene-related peptide in unanesthetized trout. J Exp Biol 2012; 215:1930-7; PMID:22573772; http://dx.doi.org/10.1242/jeb.070177
34. Casey DP, Joyner MJ. Compensatory vasodilatation during hypoxic exercise: mechanisms responsible for matching oxygen supply to demand. J Physiol 2012; 590:6321-6; PMID:22988134; http://dx.doi.org/10.1113/jphysiol.2012.242396
35. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754-62; PMID:10993991; http://dx.doi.org/10.1212/WNL.55.6.754
36. Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, 1996.
37. Roguin A. Henry Cuthbert Bazett (1885-1950) - the man behind the QT interval correction formula. Pacing Clin Electrophysiol 2011; 34:384-8; PMID:21091739; http://dx.doi.org/10.1111/j.1540-8159.2010.02973.x